Loss of imprinting or hypomethylation in the promoter region, of the insulin-like growth factor 2 (ILGF2), paternally expressed gene 1/mesoderm-specific transcript homolog protein (PEG1/MEST), and the H19 genes was also reported in lung cancer, suggesting that methylation is used not only to silence TSG, but also to activate potential oncogenes through hypomethylation [5, 6]. The gene discussed is MEST; the disease is lung carcinoma.